Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Gastroenterology · Lancet · 2026-09-30

In 880 treatment-naive adults with non-cirrhotic chronic hepatitis C in India, 8 weeks of sofosbuvir-velpatasvir was non-inferior to 12 weeks for SVR12 (per-protocol 98·8% vs 99·0%; risk difference 0·2%), with no drug-related serious adverse events.

RCTn = 880
Goel et al. 8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India
Gastroenterology · Lancet Gastroenterol Hepatol · 2026-08-26

In 102 non-cirrhotic adults with presumed MASH (F1–F3), 12 weeks of the THR-β agonist ALG-055009 cut MRI-PDFF liver fat vs placebo; placebo-adjusted relative change −33.2% at 0.7 mg and −31.6% at 0.9 mg, not significant at 0.3 mg. No safety signals seen.

RCTn = 102
Loomba et al. ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial
Gastroenterology · Lancet Gastroenterol Hepatol · 2026-08-25

In 342 patients with untreated unresectable hepatocellular carcinoma, adding atezolizumab plus bevacizumab to on-demand TACE lengthened median TACE-PFS (11.3 vs 7.0 months; HR 0.71). Overall survival, immature at interim analysis, showed no difference (HR 0.96).

RCTn = 342
Kudo et al. On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.